Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole SodiumCategory 1.1 Ne...

HONG KONG, 17 July 2013 – Sihuan Pharmaceutical Holdings Group Ltd. announced that Anaprazole Sodium, a Category 1.1 new drug received the Approval for Clinical Studies from the State Food and Drug Administration (“SFDA”) of the People’s Republic...

Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole SodiumCategory 1.1 New Drug Clinical Studies
2014-04-10
Beijing Sihuan was successfully enlisted for phase II G20 enterprises

Beijing Sihuan was successfully enlisted for phase II G20 enterprises. At the same time, Kelinao, the product of Beijing Sihuan Pharmaceutical Co., Ltd. received the certificate of Outstanding Contribution to the G20 project.

2014-03-11
Sihuan Pharmaceutical Announces 2013 Annual Results

Sihuan Pharmaceutical Announces 2013 Annual Results, Revenue and Profit Attributable to Owners of the Company, Up by 55.6% and 44.1% Respectively

2013-12-12
Sihuan Pharm Receives "Golden Bauhinia Awards 2013"

Nov 28 2013, Hong Kong-- Sihuan Pharmaceutical Holdings Group was honored \"Listed Company with Highest Investment Value\" in the Golden Bauhinia Awards 2013 Forum. Ms Jia Zhongxin, the Chief ...

2013-10-18
Start of the first 4 volunteers in Imigliptin Dihydrochloride Phase I clinical trial

Sihuan R&D clinical research centre (based in Beijing) announced that four healthy volunteers (human subjects) were administrated Imigliptin Dihydrochloride at first dosage of 5mg this morning around 8:00 am on 18 Oct 2013, and they all are in good conditions without any observed adverse effects so far.

2013-10-10
Sihuan’s application of Catagory1.1 innovative drug Pirotinib was recently accepted by the CFDA

Sihuan today announced that Pirotinib(哌罗替尼), a Category 1.1 innovative drug which is developed by our innovative drug R&D team applied on 26thSep, was recently accepted by the CFDA(IND filling numbers 1300995 and 1300996).

Total 5 Pages  First page  Page up  Page down  Last page

Select

  • 2014
  • 2013
  • 2012